Open Access

Science

, volume 371 , issue 6530

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Paul-Albert Koenig ^{1, 2}

Hrishikesh Das ³

Hejun Liu ⁴

Beate M Kümmerer ^{5, 6}

Florian N Gohr ²

Lea Marie Jenster ²

Lisa Dj Schiffelers ²

Yonas M Tesfamariam ²

Miki Uchima ²

Jennifer Deborah Wuerth ²

Karl Gatterdam ⁷

Natalia Ruétalo ⁸

Maria H. Christensen ²

Caroline I Fandrey ²

Sabine Normann ²

Jan Mp Tödtmann ¹

Steffen Pritzl ¹

Leo Hanke ⁹

Jannik Boos ¹⁰

Meng Yuan ⁴

Xue-Yong Zhu ⁴

J. Schmid-Burgk ¹¹

Hiroki Kato ¹²

Michael Schindler ⁸

I. H. Wilson ^{4, 13}

Matthias Geyer ⁷

Kerstin U. Ludwig ¹⁰

B. Martin Hallberg ^{3, 14}

Nicholas Wu ^{15, 16, 17}

Florian I. Schmidt ^{1, 2}

Hide authors affiliations Show authors affiliations: 17 affiliations

Core Facility Nanobodies, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden. |

⁴

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. |

⁵

Institute of Virology, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

⁶

German Centre for Infection Research (DZIF), partner site Bonn-Cologne, 53127 Bonn, Germany. |

⁷

Institute of Structural Biology, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

⁸

Institute for Medical Virology and Epidemiology, Section Molecular Virology, University Hospital Tübingen, 72076 Tübingen, Germany. |

⁹

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden. |

¹⁰

Institute of Human Genetics, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

¹¹

Institute for Clinical Chemistry and Clinical Pharmacology, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

¹²

Institute of Cardiovascular Immunology, Medical Faculty, University of Bonn, 53127 Bonn, Germany. |

¹³

The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. |

¹⁴

Centre for Structural Systems Biology (CSSB) and Karolinska Institutet VR-RÅC, Notkestrasse 85, 22607 Hamburg, Germany. |

¹⁵

Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. |

¹⁶

Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. |

¹⁷

Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. |

Publication type: Journal Article

Publication date: 2021-02-12

American Association for the Advancement of Science (AAAS)

Science

scimago Q1

wos Q1

SJR: 10.416

CiteScore: 48.4

Impact factor: 45.8

ISSN: 00368075, 10959203

DOI: 10.1126/science.abe6230

Copy DOI

PubMed ID: 33436526

Multidisciplinary

Abstract

A double punch against SARS-CoV-2

Monoclonal antibodies are an important weapon in the battle against COVID-19. However, these large proteins are difficult to produce in the needed quantities and at low cost. Attention has turned to nanobodies, which are aptly named, single-domain antibodies that are easier to produce and have the potential to be administered by inhalation. Koenig et al. describe four nanobodies that bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent infection of cells (see the Perspective by Saelens and Schepens). Structures show that the nanobodies target two distinct epitopes on the SARS-CoV-2 spike protein. Multivalent nanobodies neutralize virus much more potently than single nanobodies, and multivalent nanobodies that bind two epitopes prevent the emergence of viral escape mutants.

Science , this issue p. eabe6230 ; see also p. 681

Found

1 citation

Xu H. Eric

PhD

725 publications, 21 120 citations, 8 reviews

h-index: 71

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Top-30

Journals

	2 4 6 8 10 12 14 16 18
bioRxiv	bioRxiv, 17, 4.57% bioRxiv 17 publications, 4.57%
Frontiers in Immunology	Frontiers in Immunology, 14, 3.76% Frontiers in Immunology 14 publications, 3.76%
Nature Communications	Nature Communications, 13, 3.49% Nature Communications 13 publications, 3.49%
Viruses	Viruses, 8, 2.15% Viruses 8 publications, 2.15%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 7, 1.88% International Journal of Molecular Sciences 7 publications, 1.88%
International Journal of Biological Macromolecules	International Journal of Biological Macromolecules, 6, 1.61% International Journal of Biological Macromolecules 6 publications, 1.61%
mAbs	mAbs, 6, 1.61% mAbs 6 publications, 1.61%
Scientific Reports	Scientific Reports, 5, 1.34% Scientific Reports 5 publications, 1.34%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 5, 1.34% Proceedings of the National Academy of Sciences of the United States of America 5 publications, 1.34%
Signal Transduction and Targeted Therapy	Signal Transduction and Targeted Therapy, 4, 1.08% Signal Transduction and Targeted Therapy 4 publications, 1.08%
Communications Biology	Communications Biology, 4, 1.08% Communications Biology 4 publications, 1.08%
iScience	iScience, 4, 1.08% iScience 4 publications, 1.08%
Journal of the American Chemical Society	Journal of the American Chemical Society, 4, 1.08% Journal of the American Chemical Society 4 publications, 1.08%
PLoS Pathogens	PLoS Pathogens, 4, 1.08% PLoS Pathogens 4 publications, 1.08%
Cells	Cells, 3, 0.81% Cells 3 publications, 0.81%
Vaccines	Vaccines, 3, 0.81% Vaccines 3 publications, 0.81%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 3, 0.81% Frontiers in Molecular Biosciences 3 publications, 0.81%
Journal of Biological Chemistry	Journal of Biological Chemistry, 3, 0.81% Journal of Biological Chemistry 3 publications, 0.81%
Cell Reports	Cell Reports, 3, 0.81% Cell Reports 3 publications, 0.81%
Antiviral Research	Antiviral Research, 3, 0.81% Antiviral Research 3 publications, 0.81%
ACS Nano	ACS Nano, 3, 0.81% ACS Nano 3 publications, 0.81%
Advanced Science	Advanced Science, 3, 0.81% Advanced Science 3 publications, 0.81%
Science advances	Science advances, 3, 0.81% Science advances 3 publications, 0.81%
EMBO Reports	EMBO Reports, 3, 0.81% EMBO Reports 3 publications, 0.81%
Journal of Virology	Journal of Virology, 3, 0.81% Journal of Virology 3 publications, 0.81%
Microorganisms	Microorganisms, 2, 0.54% Microorganisms 2 publications, 0.54%
Antibodies	Antibodies, 2, 0.54% Antibodies 2 publications, 0.54%
Frontiers in Microbiology	Frontiers in Microbiology, 2, 0.54% Frontiers in Microbiology 2 publications, 0.54%
Nature	Nature, 2, 0.54% Nature 2 publications, 0.54%
	2 4 6 8 10 12 14 16 18

Publishers

	10 20 30 40 50 60 70 80
Elsevier	Elsevier, 74, 19.89% Elsevier 74 publications, 19.89%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 72, 19.35% Cold Spring Harbor Laboratory 72 publications, 19.35%
Springer Nature	Springer Nature, 56, 15.05% Springer Nature 56 publications, 15.05%
MDPI	MDPI, 32, 8.6% MDPI 32 publications, 8.6%
Frontiers Media S.A.	Frontiers Media S.A., 23, 6.18% Frontiers Media S.A. 23 publications, 6.18%
American Chemical Society (ACS)	American Chemical Society (ACS), 22, 5.91% American Chemical Society (ACS) 22 publications, 5.91%
Wiley	Wiley, 22, 5.91% Wiley 22 publications, 5.91%
Taylor & Francis	Taylor & Francis, 9, 2.42% Taylor & Francis 9 publications, 2.42%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 7, 1.88% Public Library of Science (PLoS) 7 publications, 1.88%
Oxford University Press	Oxford University Press, 7, 1.88% Oxford University Press 7 publications, 1.88%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 7, 1.88% American Association for the Advancement of Science (AAAS) 7 publications, 1.88%
European Molecular Biology Organization	European Molecular Biology Organization, 6, 1.61% European Molecular Biology Organization 6 publications, 1.61%
American Society for Microbiology	American Society for Microbiology, 6, 1.61% American Society for Microbiology 6 publications, 1.61%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 5, 1.34% Proceedings of the National Academy of Sciences (PNAS) 5 publications, 1.34%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 4, 1.08% Royal Society of Chemistry (RSC) 4 publications, 1.08%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 2, 0.54% American Society for Biochemistry and Molecular Biology 2 publications, 0.54%
Microbiology Society	Microbiology Society, 1, 0.27% Microbiology Society 1 publication, 0.27%
Massachusetts Medical Society	Massachusetts Medical Society, 1, 0.27% Massachusetts Medical Society 1 publication, 0.27%
Portland Press	Portland Press, 1, 0.27% Portland Press 1 publication, 0.27%
Walter de Gruyter	Walter de Gruyter, 1, 0.27% Walter de Gruyter 1 publication, 0.27%
Cambridge University Press	Cambridge University Press, 1, 0.27% Cambridge University Press 1 publication, 0.27%
Rockefeller University Press	Rockefeller University Press, 1, 0.27% Rockefeller University Press 1 publication, 0.27%
American Institute of Mathematical Sciences (AIMS)	American Institute of Mathematical Sciences (AIMS), 1, 0.27% American Institute of Mathematical Sciences (AIMS) 1 publication, 0.27%
eLife Sciences Publications	eLife Sciences Publications, 1, 0.27% eLife Sciences Publications 1 publication, 0.27%
Scientific Scholar	Scientific Scholar, 1, 0.27% Scientific Scholar 1 publication, 0.27%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 0.27% Bentham Science Publishers Ltd. 1 publication, 0.27%
Spandidos Publications	Spandidos Publications, 1, 0.27% Spandidos Publications 1 publication, 0.27%
American Physical Society (APS)	American Physical Society (APS), 1, 0.27% American Physical Society (APS) 1 publication, 0.27%
The Royal Society	The Royal Society, 1, 0.27% The Royal Society 1 publication, 0.27%
	10 20 30 40 50 60 70 80

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

373

Cite this

GOST |

Cite this

GOST Copy

Koenig P. et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape // Science. 2021. Vol. 371. No. 6530.

GOST all authors (up to 50) Copy

Koenig P., Das H., Liu H., Kümmerer B. M., Gohr F. N., Jenster L. M., Schiffelers L. D., Tesfamariam Y. M., Uchima M., Wuerth J. D., Gatterdam K., Ruétalo N., Christensen M. H., Fandrey C. I., Normann S., Tödtmann J. M., Pritzl S., Hanke L., Boos J., Yuan M., Zhu X., Schmid-Burgk J., Kato H., Schindler M., Wilson I. H., Geyer M., Ludwig K. U., Hallberg B. M., Wu N., Schmidt F. I. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape // Science. 2021. Vol. 371. No. 6530.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1126/science.abe6230

UR - https://doi.org/10.1126/science.abe6230

TI - Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

T2 - Science

AU - Koenig, Paul-Albert

AU - Das, Hrishikesh

AU - Liu, Hejun

AU - Kümmerer, Beate M

AU - Gohr, Florian N

AU - Jenster, Lea Marie

AU - Schiffelers, Lisa Dj

AU - Tesfamariam, Yonas M

AU - Uchima, Miki

AU - Wuerth, Jennifer Deborah

AU - Gatterdam, Karl

AU - Ruétalo, Natalia

AU - Christensen, Maria H.

AU - Fandrey, Caroline I

AU - Normann, Sabine

AU - Tödtmann, Jan Mp

AU - Pritzl, Steffen

AU - Hanke, Leo

AU - Boos, Jannik

AU - Yuan, Meng

AU - Zhu, Xue-Yong

AU - Schmid-Burgk, J.

AU - Kato, Hiroki

AU - Schindler, Michael

AU - Wilson, I. H.

AU - Geyer, Matthias

AU - Ludwig, Kerstin U.

AU - Hallberg, B. Martin

AU - Wu, Nicholas

AU - Schmidt, Florian I.

PY - 2021

DA - 2021/02/12

PB - American Association for the Advancement of Science (AAAS)

IS - 6530

VL - 371

PMID - 33436526

SN - 0036-8075

SN - 1095-9203

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Koenig,

author = {Paul-Albert Koenig and Hrishikesh Das and Hejun Liu and Beate M Kümmerer and Florian N Gohr and Lea Marie Jenster and Lisa Dj Schiffelers and Yonas M Tesfamariam and Miki Uchima and Jennifer Deborah Wuerth and Karl Gatterdam and Natalia Ruétalo and Maria H. Christensen and Caroline I Fandrey and Sabine Normann and Jan Mp Tödtmann and Steffen Pritzl and Leo Hanke and Jannik Boos and Meng Yuan and Xue-Yong Zhu and J. Schmid-Burgk and Hiroki Kato and Michael Schindler and I. H. Wilson and Matthias Geyer and Kerstin U. Ludwig and B. Martin Hallberg and Nicholas Wu and Florian I. Schmidt},

title = {Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape},

journal = {Science},

year = {2021},

volume = {371},

publisher = {American Association for the Advancement of Science (AAAS)},

month = {feb},

url = {https://doi.org/10.1126/science.abe6230},

number = {6530},

doi = {10.1126/science.abe6230}

}

Publisher

American Association for the Advancement of Science (AAAS)

Journal

Science

scimago Q1

wos Q1

SJR

10.416

CiteScore

48.4

Impact factor

45.8

ISSN

00368075 (Print)

10959203 (Electronic)